Lataa...
A recurrent endometrial stromal sarcoma harbors the novel fusion JAZF1-BCORL1
• Genomic alterations may improve diagnostic certainty and subsequent treatment of endometrial stromal sarcoma. • Novel JAZF1-BCORL1 mutation was identified. • Targeted therapeutics to down-stream targets may improve survival benefit in these patients.
Tallennettuna:
| Julkaisussa: | Gynecol Oncol Rep |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Elsevier
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5348601/ https://ncbi.nlm.nih.gov/pubmed/28331900 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2017.03.002 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|